Pierre Armand Morgon

Pierre Armand Morgon currently works at Mrgn Advisors, as CEO from 2015, Drug Abuse Sciences, as CEO from 2006, MRGN Advisors SARL, as Chief Executive Officer & Manager, Ibex Therapeutics SA, as Chief Executive Officer, Kupando GmbH, as Chairman from 2021, Adiposs SA, as Non-Executive Chairman, MYCB1 Group BV, as Chairman from 2020, MYCB1 BV, as Chairman from 2020, Health Technology Holding Srl, as Chairman, Univercells SA, as Non-Executive Director from 2018, Limula SA, as Independent Non-Executive Director, Barinthus Biotherapeutics Plc, as Independent Non-Executive Director from 2018, International Association for Biologicals, as Director, Zambon Biotech SA, as Director, and CUBE Labs Srl, as Advisor.
Dr. Morgon also formerly worked at AJ Biologics Sdn.
Bhd., as Chief Executive Officer from 2014 to 2016, Virometix AG, as Chairman from 2017 to 2019, Alma Biotherapeutics, as Chairman from 2017 to 2018, Cegedim SA, as Marketing Director, Theradiag SA, as Independent Director from 2012 to 2018, CanSino Biologics, Inc., as Independent Non-Executive Director from 2018 to 2019, Schering-Plough SAS, as Director from 2006 to 2008, Barinthus Biotherapeutics (UK) Ltd., as Non-Executive Director from 2017 to 2021, Eurocine Vaccines AB, as Non-Executive Director from 2013 to 2019, Amoéba SA, as Director from 2020 to 2021, Valerio Therapeutics SA, as Chief Operating Officer from 2008 to 2009, and Sanofi Pasteur SA, as VP-Franchise & Global Marketing Strategy from 2009 to 2013.
Dr. Morgon received his undergraduate degree from INSEAD, undergraduate degree from International Institute for Management Development, Masters Business Admin degree from ESSEC Business School, doctorate degree from the University of Lyon, and graduate degree from Jean Moulin University Law School.